Munich – Immatics Biotechnologies GmbH has completed a Series C round of financing totalling some 54 million euros. The purpose of the transaction is to finance development of medicines for treating cancer.
A team headed by lead lawyer Stefan-Ulrich Müller advised Immatics Biotechnologies GmbH on the transaction.
The round of financing included both existing and new investors. Dievini Hopp Biotech holding, Wellington Partners and other existing shareholders provided around half of the funding. The other half was contributed by MIG GmbH & Co. Fonds 11 KG and AT Impf GmbH.
Advisers CMS Hasche Sigle on behalf of Immatics Biotechnologies GmbH:
Stefan-Ulrich Müller, Corporate (Lead)
Sebastian Wilhelm, Corporate
Advisers RITTERSHAUS on behalf of dievini Hopp BioTech holding GmbH & Co. KG:
Dr Corinna Mickel
Dr Martin Bürmann
Advisers Kaufmann Lutz on behalf of MIG GmbH & Co. Fonds 11 KG:
Dr Bernhard Noreisch, Corporate (Lead)
Björn Weidehaas, Corporate
Dr Susanne Adlberger, Employment Law
Carsten Huch-Hallwachs, Intellectual Property
Dr René Poew, Real Estate
Advisers RP Richter & Partner on behalf of AT Impf GmbH: